Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 57.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (33.1%)
  • Dividend yield for the last twelve months 0.8%
  • Free cash flow yield -1.6% (LTM)
  • Share price is 160.0% higher than minimum and 19.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (38.2x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $222.4 mln (-0.031% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+0.8%)770.76
year average price 799.56  


year start price 904.97 2024-09-18

max close price 932.06 2024-10-11

min close price 625.65 2025-08-08

current price 770.76 2025-09-17
Common stocks: 900 605 000

Dividend Yield:  0.8%
FCF Yield LTM: -1.6%
EV / LTM EBITDA: 38.2x
EV / EBITDA annualized: 24.7x
Last revenue growth (y/y):  +37.6%
Last growth of EBITDA (y/y):  +77.9%
Historical revenue growth:  +23.8%
Historical growth of EBITDA:  +42.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 694 150
Net Debt ($m): 36 434
EV (Enterprise Value): 730 584
EBITDA LTM ($m): 19 131
EV / LTM EBITDA: 38.2x
Price to Book: 48.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-17wsj.com

Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival

2025-09-17reuters.com

Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy

2025-09-17reuters.com

Eli Lilly cautious on using FDA fast-track voucher for weight loss pill

2025-09-16youtube.com

Lilly CEO: U.K. has gone from biopharma leader to laggard

2025-09-16youtube.com

Eli Lilly to build $5B Virginia site to boost production of targeted cancer drugs, other treatments

2025-09-16wsj.com

Eli Lilly to Invest $5 Billion in New Virginia Drug Manufacturing Plant

2025-09-16reuters.com

Focus: Lilly weight-loss pill could be FDA-approved by year-end

2025-09-16fool.com

Here Is My Top Stock Pick Among the Weight Loss Industry Leaders

2025-09-15zacks.com

Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?

2025-09-15fool.com

1 Stock That Should Be in Every Investor's Portfolio
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data